<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="942">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04729153</url>
  </required_header>
  <id_info>
    <org_study_id>DAADs and covid-19</org_study_id>
    <nct_id>NCT04729153</nct_id>
  </id_info>
  <brief_title>Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity</brief_title>
  <official_title>Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate effect of DAADs on covid-19 disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If Chronic HCV patients who already received DAADs are protected against covid 19 and&#xD;
      considered to be immune or not And if DAADS can be used in ttt of covid 19&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect of DAADs on covid -19</measure>
    <time_frame>12 months (from 1/2/2021 to 1/2/2022)</time_frame>
    <description>If chronic HCV patients who received DAADs suspected to be infected by covid-19 by having findings suggest covid 19 infection in MSCT chest or clinically symptoms or confirmed by nasopharyngeal swab . And if infected what about severity , if they need hospital admission or oxygen therapy or mechanical ventilation ,if they still alive or died</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Chronic HCV patients previously treated by DAADs.</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic HCV patients not treated by DAADs yet.</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAAD Compound</intervention_name>
    <description>Sofosbuvir , Daclatasvir and ribavirin</description>
    <arm_group_label>Chronic HCV patients previously treated by DAADs.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HCV patient with or without LC.&#xD;
&#xD;
          2. &gt;18 years old.&#xD;
&#xD;
          3. Received DAADs at 2019.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Combined HCV and HIV infected patients.&#xD;
&#xD;
          2. Combined HCV and HBV infected patients.&#xD;
&#xD;
          3. &lt; 18 years old.&#xD;
&#xD;
          4. Pregnant or breast-feeding patients.&#xD;
&#xD;
          5. Patients with autoimmune disease.&#xD;
&#xD;
          6. Patients with multiorgan failure, active cancer, renal insufficiency.&#xD;
&#xD;
          7. Patients received immunosuppressive drugs.&#xD;
&#xD;
          8. Immune compromised patients.&#xD;
&#xD;
          9. Previous confirmed diagnosis of SARS-CoV-2 before starting DAAs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Eman Adel</last_name>
    <phone>01096883754</phone>
    <email>emanadel9594@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nahed Ahmed</last_name>
    <phone>0 100 361 1626</phone>
    <email>nahedmak@yahoo.com</email>
  </overall_contact_backup>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 23, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>January 30, 2021</last_update_submitted>
  <last_update_submitted_qc>January 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Eman Adel Zareh</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

